Rhythm Pharmaceuticals is transitioning from a development stage to a commercial rare disease leader, leveraging its IMCIVREE franchise for biologically defined obesity. IMCIVREE's recent FDA and EU approvals for acquired hypothalamic obesity unlock a significant, underserved market with rapid early uptake and global expansion potential. RYTM's premium valuation is justified by rapid revenue growth, multiple approved indications, global infrastructure, and a robust pipeline targeting rare neuroendocrine obesity.